TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Australian Clinical Labs Ltd ( (AU:ACL) ) has shared an update.
Australian Clinical Labs Ltd has announced the final notification of its buy-back program, where a total of 6,042,629 ordinary fully paid securities were bought back for a total consideration of AUD 19,101,121.57. This buy-back is part of the company’s strategic financial management, potentially impacting its market positioning by reducing the number of outstanding shares, which may enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, primarily focusing on providing pathology services. The company offers a range of diagnostic testing services and is a significant player in the Australian market for clinical laboratory services.
Average Trading Volume: 1,011,653
Technical Sentiment Signal: Sell
Current Market Cap: A$501.2M
For a thorough assessment of ACL stock, go to TipRanks’ Stock Analysis page.